FDA New Drug and Biologic Approvals -- 2017 Year-in-Review

Mary L Windle, PharmD

Disclosures

January 11, 2018

In This Article

Xepi (ozenoxacin topical)

Indication:

Treatment of impetigo caused by Staphylococcus aureus or Streptococcus pyogenes in adults and children aged 2 months or older.

Mechanism:

Topical quinolone antimicrobial. Inhibits bacterial DNA replication enzymes, DNA gyrase A, and topoisomerase IV.

Dosage:

Apply a thin layer topically to affected area q12hr for 5 days; not to exceed 100 cm2 area in adults and adolescents or to exceed 2% of body surface area for children aged 2 months to 12 years.

Approval:

Approval was based on two phase 3 multicenter, randomized, double-blind, placebo-controlled studies (n=723). Both phase 3 pivotal studies demonstrated ozenoxacin cream 1% applied topical twice daily for 5 days was superior to placebo on both the clinical and the bacteriological endpoints.

Reference:

Gropper S, et al. Ozenoxacin 1% cream applied topically BID for 5 days: a multicenter, randomized, placebo- and retapamulin-controlled clinical trial. Future Microbiol. 2014;9(9):1013-23.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as:

processing....